non-steroidal anti-inflammatory drugs, 20% had at least one local corticosteroid infiltration, 34% had functional rehabilitation and 4, 1% had surgical treatment. Regarding sexual dysfunction, 34.5% of our patients didn't have any sexual activity, 2.1% had a catastrophic sexual life (score <20), 9% had a disappointing sexual life (score between 20 and 40), 20% had an average sexual life (score between 40 and 60), 17.9% had a satisfying sexual life (score between 60 and 80), while only 13.1% had a very fulfilling sexual life (score between 80 and 100. we showed that the alteration of the sexual quotient in our patients is more marked when the age of the patients is more advanced. But we didn't found a significant correlation with the duration of the disease, the mean visual analogue scale for pain and the functional scores of Quebec and Dallas. Conclusions: Our study suggests that sexuality is profoundly disrupted in chronic low back pain. The advanced age is proved to be correlated with the deterioration of the sexual life. So, sexuality must be taken into account in the management of patients with chronic low back pain. 3% had a regular sports activity and 9.7% were smokers. 38% had the habit of walking while studying. All habits were similar across years of studying except for sports activities which decreased over the years (p 0.018). 80% were satisfied with their studies. Only 46% were satisfied with their quality of sleep. Mean PHQ4 score was 7.17 and increased with the years of studies (p 0.045). 55.8% of students reported a LBP event during the past year, with a mean number of 3.6 episodes per year. 91% of these students had LBP while studying, with high reported intensity (5.18/10), 62.5% reported LBP after exercise. 80% had episodes of less than one month and 7% of more than three months duration. 12% had IBP according to the ASAS criteria (Details of IBP in Figure 1 Background: The carpal tunnel syndrome (CTS) is the most common neuropathy (1). The etiology isn't properly known, but CTS is produced by the chronic compression of median nerve while passing through carpal canal can be associated with this disease (2). Objectives: The aim of this study was to investigate the efficiency of extracorporeal shockwave therapy (ESWT) in the treatment of CTS. Methods: 49 hand with the diagnosis of CTS were included in the study. Patients were randomised in ESWT (n=29 hands) and sham (n=20 hands) groups. Patients were randomly allocated to receive 1 session per week for 3 weeks of either sham or active ESWT. All patients were prescribed with tendon and nerve gliding exercises and hand-wrist splint which used night. Patients were evaluated before the treatment, and at the end of the first week, first month and third month after the last ESWT treatment session with Boston Scale (symptom severity and functional capacity), Visual Analogue Scale (VAS) for pain and paresthesia assessment, for muscle strength hand gross grasp and electroneurophysiological parameters. Results: A total of 38 patients completed the study with 29 wrists in active ESWT and 20 wrists in sham ESWT groups. Groups were similar in age, sex, duration of symptoms, hand gross grasp and electrodiagnostic parameters (P>0.05). In both groups, significant improvements were observed in VAS, Boston Scale and hand gross grasp after treatment. In both groups, there was no statistically significant improvement in electromyographic variables after treatment (p>0.05). However there was no significiant differrence between two groups in all of clinical and electrodiagnostic parameters. Conclusions: Although ESWT was effective in symptoms in CTS but this efficacy isn't superior to placebo. Our results indicated that ESWT was effective in pain and clinical variables in CTS. Wider and high-quality studies are needed to further demonstrate the effectiveness of ESWT in treatment of CTS. Background: Lateral elbow epicondylitis, also known as tennis elbow, is a common musculoskeletal condition causing pain and functional impairment in daily activities.
1 It affects between 40-50% of recreational tennis players at some time.
2 Sodium Hyaluronate (SH) is a natural biological substance which has proven to be effective to improve pain and function in osteoarthritic patients with low incidence of side effects.
3 Similarly, the administration of periarticular injections of SH can be an alternative approach to treat chronic epicondylitis. Objectives: To evaluate the efficacy and safety of a single periarticular injection with SH in the treatment of epicondylitis. Methods: A single-site, and placebo-controlled trial was conducted in patients with chronic epicondylitis. Patients' condition was assessed at baseline and afterwards they were randomized 1:1 to receive a single 2.5ml injection of SH (manufactured by Tedec Meiji Farma SA) or placebo (saline) at the point of maximal pain at the lateral epicondyle. Additionally, standard of care (RICE: Rest, Ice, Compression and Elevation) was prescribed to both groups. Efficacy assessments were done at days 30 and 90 and included VAS (0-10cm) pain at rest and assessment of grip strength, patient global satisfaction, patient assessment of normal function and physician global assessment of elbow injury (all measured using 5-point categorical scale). Adverse events were recorded for safety purposes. Results: A total of 60 patients were included and completed the study procedures. Both groups were homogeneous at baseline. A statistically significant reduction from baseline in VAS pain at rest and after grip testing was observed at 30 and 90 days in both treatment groups (p<0.05). Besides, inter-group comparison showed statistically significant differences in favour of SH group at 30 and 90 days (p<0.05). This was associated with significantly greater grip strength, patient global satisfaction and assessment of normal elbow function in SH group vs placebo (p<0.05). Improvement of elbow injury assessed by the physician was also statistically greater in patients treated with SH compared to placebo (p<0.05). No adverse events were recorded. Conclusions: A single local injection of SH administered to patients with epicondylitis was significantly superior to placebo improving pain at rest and after grip testing, through all the study follow up period. The treatment was highly satisfactory for both physicians and patients and there were no safety concerns. Background: Iliotibial band syndrome (ITBS) is the most common cause of lateral knee pain in runners 1 . It is an overuse injury that results from repetitive friction of the iliotibial band (ITB) over the lateral femoral epicondyle. Initial treatment includes activity modification, nonsteroidal anti-inflammatory medication, taping, stretching exercise and in severe cases, a corticosteroid injection 2 . Treatment of symptoms and return to activity are variable and can be intractable. Objectives: To evaluate the efficacy and safety on pain and return to activity of a single, local injection of ITBS with combination hyaluronate and Botulinum toxin in 45 runners. Methods: 45 runners with at least grade 2 ITBS underwent baseline investigations including pain following symptom-limited treadmill running test during which pain was recorded on a visual analogue scale (VAS 0-10) every minute. Runners then had injection in the area where the iliotibial band crosses the lateral femoral condyle with 2.5 ml combination hyaluronate (750-1300 kDa) with 40 U Botulinum toxin. Additionally, standard of care (RICE: Rest, Ice, Compression and Elevation) and stretching was prescribed but participants were instructed not to use NSAIDS or taping. The same pain VAS measures as well as peak exercise time, patient global satisfaction and patient assessment of normal running function (all measured using 5-point categorical scale) were repeated after 2, 7, 14 and 30 days. The primary outcome was peak pain during symptom-limited treadmill running. Adverse events were recorded for safety purposes. Results: 45 consecutive runners with acute (within 7 days) ITBS were included and completed the study procedures. A statistically significant reduction from baseline in VAS peak treadmill exercise was observed at all time points (p<0.05). This was associated with significantly longer exercise time at 7, 14 and 30 days. Patient global satisfaction was increased progressively after 7, 14 and 30 days and assessment of normal running function was described in >75% at 14 days. No serious adverse were reported. 3 subjects described transient (<24 hours) weakness in knee extension and 2 subjects described mild pain at the time and location of injection. Conclusions: A single local injection of combination hyaluronate + Botulinum toxin for ITBS in runners improved pain and exercise time with treadmill running by 7 days post treatment and continued to 30 days. This treatment was satisfactory to runners and resulted in few, limited adverse events. 
